GlassScriptPhysician profile
Paul S White
NPI 1356607485
$2,522.36
in general payments reported to CMS, 2019-2025
28 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $232 · 2021: $85.25 · 2022: $553 · 2023: $844 · 2024: $390 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $332 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.63 |
| Education | $332.25 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $308.74 | 2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $268.80 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $212.47 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Genentech USA, INC. | $181.75 | 2019-2023 | Alecensa, Tecentriq, Gavreto |
| Genzyme Corporation | $175.65 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $152.62 | 2020-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $129.04 | 2021-2023 | Epkinly, Imbruvica |
| Seagen INC. | $115.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.23 | 2020-2023 | Ninlaro |
| Amgen INC. | $103.79 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Alexion Pharmaceuticals, INC. | $91.89 | 2019-2022 | |
| Celgene Corporation | $87.83 | 2023-2024 | Reblozyl, Opdualag |
| Jazz Pharmaceuticals INC. | $81.43 | 2022 | |
| Janssen Biotech, INC. | $72.27 | 2022-2024 | Talvey, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $66.14 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $59.50 | 2025 | Brukinsa |
| Eisai INC. | $36.94 | 2023 | |
| Sobi, INC | $36.76 | 2023 | |
| Mirati Therapeutics, INC. | $36.25 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $35.43 | 2021-2023 | Fotivda |
| Blueprint Medicines Corporation | $31.66 | 2022 | |
| Pfizer INC. | $29.94 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $24.50 | 2022 | |
| Sumitomo Pharma America, INC. | $24.26 | 2023 | Orgovyx |
| Puma Biotechnology, INC. | $18.04 | 2023 | |
| Myriad Genetic Laboratories, INC. | $15.50 | 2024 | Myrisk |
| Cti Biopharma Corp. | $14.73 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.